inventivapharma.com - IVA Profit before payment of interest, taxes and amortization

Brandmark of Inventiva (IVA)

Stringent FDA requirements for the NASH treatment market create a significant barrier to entry for competitors. Inventiva S.A. is overcoming this through partnerships with Asian holdings for the global distribution of fibrosis drugs. Operating accruals before depreciation help assess the resilience of the model, where 0.00 forms the current metric indicator. The company's future pricing power depends directly on securing patents for unique developments.

Inventiva Corp (IVA) Profit before payment of interest, taxes and amortization: for the period 11/23/2025 - 11/10/2026

Summary analytical data breakdowns for Inventiva (IVA)

- stock value and consensus price forecast:
Market Chart Inventiva Corp|IVA - Consensus Target
- issuer market value details:
Market Value Inventiva|IVA - Enterprise Value
- business book valuation details:
Net Asset Value per Share Inventiva|IVA - Company Book Value|Market Value to Book Value inventivapharma.com|IVA - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital Coefficient Inventiva S.A.|IVA - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Inventiva SA|IVA - Company Total Debt|Debt to Book Capitalization Ratio Inventiva|IVA - Company Long-Term Debts|Short-Term Debt Inventiva|Immediate Liquidity Ratio inventivapharma.com
- earnings and market multiples details:
IVA - Net Income|Future Net Profit Inventiva S.A.|IVA - P/E Multiple|Market Cap to Projected Earnings inventivapharma.com|IVA - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inventiva|IVA - Operating profit EBITDA|Net earnings per share (EPS TTM) Inventiva|IVA - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months inventivapharma.com|IVA - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Inventiva S.A.
Fundamental company valuation:Inventiva Corp (IVA)
Signature product of Inventiva Corp

The scale of Inventiva S.A. (IVA) operations is reflected in the EBITDA. This metric captures the cash flow from core operations, stripped of non-cash charges and financial expenses. It measures the efficiency of converting capital into real income. For a biopharmaceutical business with a narrow focus on MASH, this indicator confirms the impact of Asian partner payments on liquidity. Growth in this figure signals a sustainable expansion of operational capacity.

Who Inventiva S.A. competes with

Operating income before deduction of amortization Arrowhead Corp (ARWR)|MIRM: Operating profit before deduction of amortization|DVAX: Profit before payment of interest, taxes and amortization|ABUS: Operating profit EBITDA|Profit before interest, taxes and amortization Gyre Therapeutics Inc (GYRE)|Profit before payment of interest, taxes and amortization Assembly Biosciences Inc|GALT: Income before deduction of interest, taxes and amortization|Operating profit EBITDA GNFT|Operating income before deduction of amortization durect.com|Profit before payment of interest, taxes and amortization Aligos Therapeutics, Inc. ALGS|BIVI: Operating profit before amortization|GLMD: Operating profit before deduction of amortization|NDRA: Profit before payment of interest, taxes and amortization|HEPA: Operating profit EBITDA